Amgen and Allergan's ABP 980 (biosimilar- Herceptin) Receives CHMP Recommendation for Three Types of Cancer
Shots:
- The CHMP recommendation is based on P-III study results assessing ABP 980 in adult female patients with HER2-positive early breast cancer
- The P-III study resulted in analytical- PK- pharmacology- toxicology data with efficacy- safety and immunogenicity in patients
- ABP 980 (trastuzumab) is a recombinant DNA-derived mIgG1 kappa Ab indicated for HER2-overexpressing early BC- adjuvant BC- mBC and metastatic gastric cancer. In Dec- 2011 Amgen & Allergan formed a collaboration to develop & commercialize four oncology Ab biosimilars
Ref: Amgen | Image: Thailand Medical News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com